Abstract
Objective: Surgery is the treatment for male lower urinary tract symptoms (LUTS) relat-ed to benign prostatic obstruction (BPO) refractory to pharma-cological treatment or with complications. This study aimed to assess factors associated with the need for surgical reinterven-tion and/or continuation of pharmacological treatment. Materials and methods: A retrospective analysis of patients who underwent prostatic surgery for male LUTS associated with BPO between 1 May 2015 and 1 May 2016, with a minimum follow-up of five years, in an academic tertiary hospital. The type of surgery, preoperative, postoperative and follow-up analysis were collected in a database. Results: A total of 212 patients were included with a mean age of 70 ± 8.66 years at five years follow-up. At 5 years, a total of 86.9% of patients do not need pharmacological treatment and 12% required surgical reintervention. Of the preoperative parameters, it was found a relationship between prior prostatitis and the need for second surgery with an odds ratio of 4.6.
Conclusions: Patients should be informed of the potential need for pharmacological treatment following surgery, or even of the need for reintervention. History of prostatitis seems to be a risk factor for reintervention.
Reference31 articles.
1. Kupelian V, Wei JT, O’Leary MP, et al. Prevalence of lower uri-nary tract symptoms and effect on quality of life in a racially and eth-nically diverse random sample: The Boston Area Community Health (BACH) survey. Arch Intern Med. 2006; 166:2381-7.
2. Gravas S, Cornu JN, Gacci M, et al. Management of non-neuro-genic male lower urinary tract symptoms (LUTS), incl. benign pro-static obstruction (BPO). Eur Assoc Urol Guidelines [Internet]. 2021; Available from: https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Non-Neurogenic-Male-LUTS-incl.-BPO-2020.pdf
3. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)-Incidence, manage-ment, and prevention. Eur Urol. 2006; 50:969-80.
4. Reich O, Gratzke C, Bachmann A, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 Patients. J Urol. 2008; 180:246-9.
5. Roehrborn CG. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia. Int J Impot Res. 2008; 20 (Suppl. 3): S19-26